Abbvie selloff overdone, says Barclays: 5 big analyst picks
Investing.com — Here is your Pro Recap of the biggest analyst picks you may have missed today: upgrades at PTC, Abbvie, East West Bancorp , Eastman Chemical, and L3Harris Technologies.
InvestingPro subscribers got this news first. Never miss another market-moving headline.
AbbVie (NYSE:ABBV) shares climbed premarket Monday after Barclays upgraded the pharmaceutical name to Overweight from Equalweight and raised its price target to $170.00 from $160.00.
The analysts said Friday's 4.3% selloff, which followed better-than-expected Q3 results, «looks like an over-reaction to external sector dynamics, against a backdrop of Immunology momentum and commentary de-risking '24 pricing.»
Shares were up 1% to $140.28 in premarket trading.
East West Bancorp (NASDAQ:EWBC) shares were rising in the premarket after UBS upgraded the bank to Buy from Neutral and raised its price target to $61.00 from $57.00.
UBS analysts said that, having reviewed the company’s Q3 numbers from earlier this month, «We now have mild upside to our 2024 estimates vs. consensus, and think the shares… are attractive in the current environment.»
The analysts also cited its «enviable» ability to deliver strong return on assets and repurchase over 3% of its shares outstanding in the next few quarters while still outpacing peers in tangible book value growth per share. They added, «The commitment to return capital to shareholders starting in 4Q also signals to us that management, while realistic about credit, is confident in the balance sheet.»
Shares were up 1.6% to $52.64 in recent premarket trading.
JPMorgan upgraded Eastman Chemical (NYSE:EMN) to Overweight from Neutral with a price target of $90.00 following a Q3 beat from the specialty-chemicals company, once
Read more on investing.com
